Literature DB >> 10903381

Rational drug design and high-throughput techniques for RNA targets.

T Hermann1, E Westhof.   

Abstract

RNA molecules are the only known molecules which possess the double property of being depository of genetic information, like DNA, and of displaying catalytic activities, like protein enzymes. RNA molecules intervene in all steps of gene expression and in many other biological activities. Like proteins, RNAs achieve those biological functions by adopting intricate three-dimensional folds and architectures. Further, as in protein sequences, RNA sequences contain signatures specific for three-dimensional motifs which participate in recognition and binding. In regulatory pathways, RNA molecules exist in equilibria between transient structures differentially stabilized by effectors such as proteins or cofactors. Therefore, RNA molecules display their potential as drug targets on different levels, namely in three-dimensional folds, in structural equilibria and in RNA-protein interfaces. Several examples will be described together with the already available techniques for combinatorial synthesis and high-throughput screening of potential drug and target RNA molecules.

Mesh:

Substances:

Year:  2000        PMID: 10903381     DOI: 10.2174/1386207003331652

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  13 in total

1.  Crystal structure of the HCV IRES central domain reveals strategy for start-codon positioning.

Authors:  Katherine E Berry; Shruti Waghray; Stefanie A Mortimer; Yun Bai; Jennifer A Doudna
Journal:  Structure       Date:  2011-10-12       Impact factor: 5.006

Review 2.  Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery.

Authors:  Sai Shashank Chavali; Rachel Bonn-Breach; Joseph E Wedekind
Journal:  J Biol Chem       Date:  2019-05-12       Impact factor: 5.157

3.  Binding of tobramycin leads to conformational changes in yeast tRNA(Asp) and inhibition of aminoacylation.

Authors:  Frank Walter; Joern Pütz; Richard Giegé; Eric Westhof
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

4.  Shortening the HIV-1 TAR RNA Bulge by a Single Nucleotide Preserves Motional Modes over a Broad Range of Time Scales.

Authors:  Dawn K Merriman; Yi Xue; Shan Yang; Isaac J Kimsey; Anisha Shakya; Mary Clay; Hashim M Al-Hashimi
Journal:  Biochemistry       Date:  2016-08-04       Impact factor: 3.162

5.  Optimized high-throughput screen for hepatitis C virus translation inhibitors.

Authors:  Katherine E Berry; Betty Peng; David Koditek; Douglas Beeman; Nikos Pagratis; Jason K Perry; Jay Parrish; Weidong Zhong; Jennifer A Doudna; I-hung Shih
Journal:  J Biomol Screen       Date:  2011-02

Review 6.  Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin.

Authors:  Shiraz Mujtaba; Ming-Ming Zhou
Journal:  Methods       Date:  2010-09-07       Impact factor: 3.608

7.  Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design I: discovery of anticancer compounds.

Authors:  Humberto Gonzáles-Díaz; Ornella Gia; Eugenio Uriarte; Ivan Hernádez; Ronal Ramos; Mayrelis Chaviano; Santiago Seijo; Juan A Castillo; Lázaro Morales; Lourdes Santana; Delali Akpaloo; Enrique Molina; Maikel Cruz; Luis A Torres; Miguel A Cabrera
Journal:  J Mol Model       Date:  2003-09-16       Impact factor: 1.810

Review 8.  Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.

Authors:  Sebastien E Emonet; Shuzo Urata; Juan C de la Torre
Journal:  Virology       Date:  2011-02-15       Impact factor: 3.616

Review 9.  Guardian of Genetic Messenger-RNA-Binding Proteins.

Authors:  Antje Anji; Meena Kumari
Journal:  Biomolecules       Date:  2016-01-06

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.